FDA approves TherapeuticsMD's ANNOVERA sNDA, boosting supply by ~7,000 rings

TherapeuticsMD, Inc.

FDA approved sNDA for ANNOVERA with revised in vitro release testing specification to allow normal manufacturing variability.
Company expects ~7,000 additional rings to enter supply chain in Q2/Q3 2022, reducing batch rejections.
CEO Hugh O'Dowd says approval enables scaling production to meet increasing customer demand for procedure-free birth control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.